Compare Adaptive Biotechnologies Corp (ADPT) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dicks Sporting Goods Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.23 (market cap $4.04B), while Dicks Sporting Goods Inc trades at $201.93 (market cap $18.35B). The key difference: Dicks Sporting Goods Inc is far larger — about 4.5× Adaptive Biotechnologies Corp's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DKS | |
|---|---|---|
Market Cap | $4.04B | $18.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $239.17 |
52-Week Low | $12.30 | $187.78 |
Enterprise Value | $4.10B | $25.14B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Dick's Sporting Goods (DKS) trades at $201.95, down 5.67% in the past 24 hours, with technical indicators showing a bearish trend and key support at $198. Fundamentally, the company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.90 beating expectations, and maintains solid profitability with a 32.21% gross margin and 20.9% ROE. Recent news highlights analyst upgrades and positive coverage, while the company announced a $1.25 dividend payable in June 2026.
The outlook for DKS is mixed; analyst consensus is bullish with a $263.22 price target and no sell ratings, but technical weakness and a recent decline pose near-term risks. Investment opportunities include undervaluation based on a P/E of 19.96 and accelerating sales growth, while risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder litigation news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
